AAV-BDNF gene therapy / MeiraGTx - LARVOL DELTA

MeiraGTx shares jump on $200M deal with Hologen AI for Parkinson's therapy (Firstwordpharma Press Release) - "...on Thursday following an announcement that the company will partner with Hologen AI to leverage its multimodal generative AI (genAI) models to accelerate Phase III development of the biotech's AAV-GAD gene therapy for Parkinson’s disease...MeiraGTx will receive an upfront cash payment of $200 million from Hologen, and together, the partners will launch a joint venture called Hologen Neuro AI. The genAI firm will also contribute $230 million in funding for the JV, which will shepherd AAV-GAD through development to commercialisation. The capital will help support other early-stage clinical programmes targeting the central nervous system (CNS), such as AAV-BDNF for genetic obesity...MeiraGTx will retain 30% ownership in Hologen Neuro AI and take the lead on all clinical development and manufacturing. It will form exclusive clinical and commercial manufacturing supply agreements with the JV."

Licensing / partnership • Obesity • Parkinson's Disease